Accent Therapeutics, a clinical-stage biopharmaceutical company pioneering novel, targeted, small molecule cancer ...

Race Oncology has submitted the ethics and regulatory package for its phase I clinical trial of RC220 bisantrene to the ...

The gelded son of Unified ran seventh in the G1 Champagne after an impressive debut, so gets class relief here ...

Sent off at just over even money to stretch her current winning streak to three, Kehoe Beach (Omaha Beach) was allowed a very ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

At the Breakthroughs in Muscular Dystrophy special meeting held in Chicago Nov. 19-20, 2024, and organized by the American Society of Gene & Cell Therapy (ASGCT), multiple interventions at the RNA ...

Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...

Korro Bio, Inc. (NASDAQ:KRRO) is making waves in the biotechnology sector with its innovative RNA editing platform, positioning itself as a potential leader in the treatment of Alpha-1 Antitrypsin ...

Korro Bio, Inc. (NASDAQ:KRRO) is making waves in the biotechnology sector with its innovative RNA editing platform, positioning itself as a potential leader in the treatment of Alpha-1 Antitrypsin ...